Alethio Therapeutics (NASDAQ: ALTH) Launches ATX-011 Antibody Targeting Essential Thrombocythemia
Key Developments Alethio Therapeutics (NASDAQ: ALTH) has introduced ATX-011, an innovative, mutation-agnostic antibody designed to treat Essential Thrombocythemia (ET), representing a market valued around $2 billion. This new treatment candidate aims to transform care for patients suffering from ET, a serious myeloproliferative neoplasm. In parallel with this announcement, Alethio Therapeutics has bolstered its leadership team by appointing Dr. Steve R. Coats, a seasoned expert in biologics development, as Chief Development…
